Z1 International to distribute OsCare Sono™ in the Middle East
VANTAA, Finland — Oscare Medical Oy announces that it will be demonstrating its novel low frequency ultrasound device, the OsCare Sono™ for osteoporosis assessment, at this year’s Arab Health together with Z1 International, at stand Z4T01. Arab Health is the region’s largest medical exhibition and will be held on 26th – 29th January in Dubai, UAE.
A novel Quantitative ultrasound (QUS) device, the OsCare Sono™ assesses bone strength in the forearm radial bone. By using very low frequency ultrasound, the measurement results correlate with bone cortical thickness, bone elasticity and bone mineral density (BMD), including BMD of the deeper cortical layers – suggesting that the OsCare Sono™ offers enhanced sensitivity to early osteoporotic changes.
Founded in 2014, Z1 International is a new, energetic medical devices distributor company that covers the Middle East markets. Z1 General Manager Mohammad Zein commented: ”We are pleased to introduce the OsCare Sono™ to the Middle East markets. We believe there will be keen interest in an easy to use, non-invasive assessment device for this increasingly prevalent disease”. The International Osteoporosis Foundation (IOF), a non-profit, nongovernmental umbrella organization, considers osteoporosis a “neglected” disease in the Middle East. Demographic and socioeconomic changes in the region have contributed to the rise of this disease and its burden on the populations and healthcare systems. Furthermore, the IOF states that access to X-ray absorptiometry machines to measure bone mineral density is extremely limited (1). This emphasizes the importance of easily accessible screening methods.
About the OsCare Sono™
The OsCare Sono™ is a compact, hand-held device designed for use in clinics and low-threshold locations, such as high street pharmacies. The device offers a convenient way of assessing skeletal bone health and is a promising new screening tool for identifying people at an increased relative risk for osteoporosis and, potentially, bone fractures. A measurement is taken from the forearm over a few minutes using harmless ultrasound. Proprietary algorithms compensate for the effects of soft tissues. An individual’s measurement is compared to the normal value observed in healthy young women, and the final OsCare Sono™ result is ready within seconds for counseling.
About Oscare Medical
Oscare Medical was founded in 2007 to commercialize the results of a decade of research into bone health at the University of Jyväskylä, Finland. Since 2013, Oscare Medical has been majority-owned by Nasdaq-OMX-listed Revenio Group Corp and is now part of the Revenio Health Tech segment which includes the hugely successful Icare® tonometer product family. The OsCare Sono™ is CE-marked and available in multiple international markets. Oscare Medical is actively expanding its distribution partner network. See: www.oscaremedical.com.
Sales & Marketing Manager
T: +358 40 732 4904
Contact for Middle East sales:
Dubai Knowledge Village, Block 3
P.O. Box: 50221
T: +971 4 453 990
Mobile: +971 55 865 4515